New cancer drug trial targets specific genetic weakness

NCT ID NCT06561685

Recruiting now Disease control Sponsor: Eli Lilly and Company Source: ClinicalTrials.gov ↗

Summary

This study is testing a new drug called LY4050784 for people with advanced solid tumors that have a specific genetic change called a SMARCA4/BRG1 alteration. The main goals are to find a safe dose of the drug, given alone or with other cancer treatments, and to see if it helps shrink or control the cancer. The study is open to adults with certain advanced cancers, including lung cancer, who have few or no other standard treatment options.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Study contacts

Contact

Email: •••••@•••••
Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Aichi Cancer Center Hospital
RECRUITING

Nagoya, 464-8681, Japan
Charite-Universitatsmedizin Berlin
NOT_YET_RECRUITING

Berlin, 10117, Germany
Columbia University Medical Center
RECRUITING

New York, New York, 10032, United States
Dana-Farber Cancer Institute
RECRUITING

Boston, Massachusetts, 02215, United States
Florida Cancer Specialists ORLANDO/DDU
RECRUITING

Lake Mary, Florida, 32746, United States
Hospital Universitari Vall d'Hebron
NOT_YET_RECRUITING

Barcelona, 08035, Spain
Institut Bergonie
NOT_YET_RECRUITING

Bordeaux, 33 076, France
Institut Curie
RECRUITING

Paris, 75248, France
Institut Gustave Roussy-Gustave Roussy Cancer Center -DITEP
NOT_YET_RECRUITING

Villejuif, 94800, France
Krankenhaus Nordwest
NOT_YET_RECRUITING

Frankfurt am Main, 60488, Germany
MD Anderson Cancer Center
RECRUITING

Houston, Texas, 77030-4009, United States
Massachusetts General Hospital
RECRUITING

Boston, Massachusetts, 02114, United States
Medical College of Wisconsin
RECRUITING

Milwaukee, Wisconsin, 53226, United States
Memorial Sloan Kettering Cancer Center
RECRUITING

New York, New York, 10065, United States
National Cancer Center
NOT_YET_RECRUITING

Ilsandong-gu, 10408, South Korea
National Cancer Center Hospital
RECRUITING

Chūōku, 104-0045, Japan
National Cancer Center Hospital East
RECRUITING

Kashiwa, 277-8577, Japan
Ohio State University Hospital
RECRUITING

Columbus, Ohio, 43210, United States
SCRI Oncology Partners
RECRUITING

Nashville, Tennessee, 37203, United States
Sarah Cannon Research Institute
RECRUITING

Nashville, Tennessee, 37203, United States
Sarah Cannon Research Institute at HealthOne
RECRUITING

Denver, Colorado, 80218, United States
Severance Hospital, Yonsei University Health System
NOT_YET_RECRUITING

Seoul, 03722, South Korea
Shizuoka Cancer Center
RECRUITING

Nagaizumi-cho,Sunto-gun, 411-8777, Japan
South Texas Accelerated Research Therapeutics (START) Madrid - Hospital Fundacion Jimenez Diaz
NOT_YET_RECRUITING

Madrid, 28040, Spain
The Cancer Institute Hospital of JFCR
RECRUITING

Kōtō City, 135-8550, Japan
The Catholic University of Korea, St. Vincent's Hospital
NOT_YET_RECRUITING

Suwon, 16247, South Korea
UCLA
NOT_YET_RECRUITING

Santa Monica, California, 90404, United States
USO-Virginia Cancer Specialists, PC
RECRUITING

Fairfax, Virginia, 22031, United States
Universitaetsklinikum Essen
NOT_YET_RECRUITING

Essen, 45147, Germany
University of Chicago
RECRUITING

New Lenox, Illinois, 60451, United States
University of Colorado Health Hospital
NOT_YET_RECRUITING

Aurora, Colorado, 80045, United States
University of Miami
RECRUITING

Miami, Florida, 33136, United States
Vanderbilt-Ingram Cancer Center
NOT_YET_RECRUITING

Nashville, Tennessee, 37232-6307, United States

Conditions

Explore the condition pages connected to this study.

ADVANCED SOLID TUMOR METASTATIC SOLID TUMOR NON SMALL CELL LUNG CANCER SMARCA4-DEFICIENT TUMOR